Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ATLANTA, GA - July 24, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: ...

Positive EMA Scientific Advice Positions GeoVax for Expedited European Approval ATLANTA, GA - July 21, 2025 (NEWMEDIAWIRE) - ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

ATLANTA, GA - June 25, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases and cancers, ...

GeoVax's intellectual property estate now encompasses over 135 granted or pending patent applications across 23 distinct patent families, reinforcing the company's strategic position across ...

GeoVax’s development-stage continuous avian cell line process is anticipated to provide increased production of MVA-based vaccines, the ability to quickly respond to epidemics and pandemics ...

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER. BC, July 16, 2025 /PRNewswire/ -- As lawmakers weigh potential cuts to scientific research ...

As lawmakers weigh potential cuts to scientific research funding, the outlook for developing cancer cures faces growing uncertainty.

Review the current Geovax Labs Inc (GOVX:XNAS) dividend yield and history to decide if GOVX is the best investment for you.

Review quarterly and annual revenue, net income, and cash flow for Geovax Labs Inc (GOVX:XNAS) stock through the last fiscal year.

Get today's GeoVax Labs stock news. We cover the latest GeoVax Labs headlines and breaking news impacting GeoVax Labs stock performance.